Kidney transplantation is a treatment of choice for patient with end stage renal disease. Chronic renal failure is characterized with weak cellular and humoral immunity. In our paper we present our experience with presence of malignancy in renal transplant patients. Urology clinic in Belgrade transplanted 411 patients over the period of 16 years. Living donor transplantation was performed for 272 and cadaveric kidney transplant for 139 patients. In the postoperative follow up, malignancies were diagnosed in 7 of the transplanted patients. Three patients developed basal cell skin carcinoma, one was diagnosed with adenocarcinoma of the transplanted kidney, one developed transitional cell carcinoma of the bladder and testicular tumors were diagnosed in two patients. Postoperative immunosuppressive therapy usually double or triple when patients are in the immunological high risk group. Incidence of malignancy according to big health centers is around 1 in every 1000 transplanted patients. It is also noted the rise of incidence of malignancies in transplanted patient in over 50%.
INTRODUCTION

R
enal transplant is the treatment of choice for patients with chronic renal failure. It prologs life, reduces morbidity, improves the quality of life and enables social rehabilitation of patients with end stage renal disease. Renal transplantation is a surgical procedure with inherent risk due to anesthesia and surgical procedure itself. There are a few generally accepted contraindications to transplantation: active infection, malignancy, substance abuse or non-adherence to therapy, chronic illness with life expectancy less than one year and poorly controlled psychosis 1 . In ESRD patient medical background and comorbidities are crucial at the time of considering a renal transplant candidate because they can determine the procedure success. Potential one renal transplant candidates must undergo thorough screening for exclusion of malignant diseases, with the individual approach to each patient. Pre-existing malignancies should be extensively evaluated before proceeding to transplantation 2 . Cancer is a frequent and recognized complication of organ transplantation. The need of continuous immunosuppressive therapy may lead to immunosupression-related side effects and direct oncologic effect. Kidney transplant recipients frequently suffer skin infection and malignancies due to the effect of long term immunosuppressive therapy 3 .
MATERIAL AND METHODS
On Urology clinic in Belgrade there have been 411 kidney transplants performed over the period of 16 years. We performed a retrospective review of medical data for these patients in this period. Living donor transplantation was performed for 272 and cadaveric kidney transplant for 139 patients. The age of the patient who underwent kidney transplant was from 8 to 64 years of age in average 39.8. Time spent on dialysis before undergoing kidney transplant was from 11 to 144 months in average 36.8.
RESULTS
In the postoperative follow up, malignancies were diagnosed in 7 of the transplanted patients. Three of the patients developed basal cell skin carcinoma, one was diagnosed with adenocarcinoma of the transplanted kidney, one developed transitional cell carcinoma of the bladder and testicular tumor was diagnosed in two patients.
Two of the patients who developed basal skin cancer underwent living donor and one underwent cadaveric kidney transplantation. Two of the patients were adminis- One patient developed adenocarcinoma of the transplanted kidney was on immunosuppressive therapy with azotioprine and steroids and was diagnosed nine year after the cadaveric transplantation and the allograft nephrectomy was performed.
One of the transplanted patients developed stage G3 transitional cell carcinoma of the bladder 49 months after the kidney transplant. Two of the transplanted patients developed testicular tumor in the period from 26 to 72 months after the KT.
Both the patient with TCC of the bladder and two of the patients who developed testicular cancer were on triple immunosuppressive therapy. They underwent surgery, radical orchyectomie and radical cystectomy were performed with administration of the chemo therapy.
Patients with the skin carcinoma were treated only surgically with excision of the diagnosed leasons. Four of the patients died as the result of the malignancies after transplantation.
DISCUSSION
Pretransplant medical evaluation aims to diagnose, treat and optimize any preexisting disease and how these can interfere with patient and graft survival. It is important to consider age, cardiovascular disease, and presence of diabetes mellitus, coagulation disorders, obesity, gastrointestinal diseases, active infection and non compliance with treatment and follow up. Some of the urological diseases may not be obvious in the anuric patient and must be considered 1 . Development of the cancer after transplantation is a recognized complication of the continuous immunosuppressive therapy and can lead to immunosupression related side effects and direct oncogenic effect.
Renal cell carcinoma are rarely described in transplanted patients. Available therapeutic strategies range from allograft nephrectomy to nephron-sparing surgery. Percutaneous radiofrequency ablation is only described in the few cases of the transplanted settings 4 . Skin tumors, in particular squamos cell carcinoma are the most common malignant condition in the transplanted patients.
The histological diagnoses include squamose cell carcinoma 50%, basal cell carcinoma 37.5% and malignant melanoma in 12.5% 5 . Skin cancer are increased in the transplanted population.
Main risk factors for skin carcinoma are fair skin type and long term immunosuppressive therapy. A follow-up program is necessary for early detection and precancerous conditions. Preventive strategies should include specialist dermatological monitoring and examination 6 . The single cases of the orthotopic ileal neobladder reconstruction in patients with squamous cell carcinoma of the bladder have been reported. It has been shown that this procedure is safe and feasible in kidney transplant 7 .
SUMMARY POJAVA MALIGNITETA KOD BOLESNIKA POSLE TRANSPLANTACIJE BUBREGA -NA[A ISKUSTVA
Transplantacije bubrega je terapija izbora za bolesnike sa terminalnom bubre'nom insuficijencijom. Karakteristika hroni~ne bubure'ne insuficijencije je oslabljen homoralni i celularni imunitet. U ovom radu predstavljamo naše iskustvo sa pojavom maligniteta kod transplantiranih bolesnika. Na Urološkoj klinici u Beogradu je transoplantirano 411 bolesnika u periodu od 16 godina. 272 bolesnika je primilo bubreg od rodjaka -living donor, a kadaveri~na transplantacija je u~injena kod 139 pacijenata. Tokom postoperativnog pra}enja u periodu od 36 do 60 meseci došlo je do pojave maligniteta kod sedam transplantiranih bolesnika. Kod tri bolesnika je dijagnostikovan tumor bazalnih }elija ko'e, kod jedne bolesnice je dijagnostikovan adenokarcinom transplantiranog bubrega. Jedan bolesnik je dijagnostikovan sa TCC mokra}ne bešike a u dva slu~aja je došlo do pojave testikularnog karcinoma.
Postoperativna imunosupresivna terapija je obi~no dvostruka, ili trostruka kod bolesnika u grupi sa povišenim imunolo{kim rizikom. Incidenca maligniteta prema rezultatima velikih zdravstvenih centara iznosi oko 1 prema 1000 transplantiranih bolesnika. Takodje je prime}en porast incidence rizika od razvoja karcinoma u preko 50%.
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